
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort is benefiting from an inflecting cell and gene therapy market, where commercial therapies are expanding quickly and management cited 23 commercial therapies supported, 788 clinical trials, and 20% commercial revenue growth in 3Q26. Revenue rose 14% y/y to $50.2M, led by 18% growth in Life Sciences Services, while adjusted EBITDA turned positive at $1.1M versus -$0.6M in 3Q25, showing operating leverage as demand improves. The outlook is further supported by a strong cash position of about $393.1M, new global supply chain centers in California and France, and upcoming approvals that could deepen visibility and lift higher-margin service revenue.
Bears say
CryoPort is challenged by slowing revenue growth if cell and gene therapy approvals come in below expectations, which would also pressure margins and profitability across its heavily services-driven business. Its operating model carries meaningful execution risk because cryogenic shipments must meet rigorous standards, while third-party carrier dependence, lengthy customer onboarding, and reliance on third-party software can disrupt service delivery, damage reputation, and expose the company to litigation and lost revenues. Competitive and regulatory pressures remain elevated, and continued weakness in MVE freezer demand suggests that even the Life Sciences Products segment may face ongoing headwinds.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CryoPort (CYRX) Forecast
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares